RADY-BTG-JOHNSON-TS102; A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy (EPOCH)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to see if adding TheraSphere treatment at the beginning of second-line chemotherapy extends survival time and is safe.
Description
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy.
Details
| Condition | Colorectal Cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX2471 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.